The following data were presented at the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals meeting in Chicago.• 4SC AG, of Planegg-Martinsried, Germany, presented final results from its Phase IIb COMPONENT study that demonstrated substantial anti-inflammatory activity of vidofludimus in rheumatoid arthritis. The international, multicenter, randomized study evaluated the efficacy of vidofludimus in combination with methotrexate (MTX) compared with MTX alone.